Bruker Corporation Appoints William J. Knight to Chief Operating Officer and Brian P. Monahan to Chief Financial Officer
November 09 2009 - 6:00AM
Business Wire
Bruker Corporation (NASDAQ: BRKR) today announced that its Board
of Directors has appointed Bill Knight to Chief Operating Officer
(COO) and Brian Monahan to Chief Financial Officer (CFO), with an
effective date of February 1st, 2010. Presently, Bill Knight is
serving as CFO, and Brian Monahan is serving as Chief Accounting
Officer of Bruker Corporation.
Frank Laukien, Bruker’s President and CEO, stated: “Bruker has a
49 year proud history of technology leadership and customer-focused
product innovation. Going forward, we believe that the combination
of continued innovation and an increased focus on operational
excellence will drive margin expansion, balance sheet metrics and
cash flow for increasing shareholder value. In order to drive our
operational excellence initiative, we have created the new position
of Chief Operating Officer at Bruker Corporation.”
He continued: “Today, we are very pleased to announce the
promotion of two extremely capable individuals to expanded
responsibilities. Over the past five years, Bill Knight has
demonstrated strong financial and operational leadership at Bruker,
and in his newly-created COO role Bill will lead and fully focus on
our operation excellence initiative. Brian Monahan has been a key
leader and contributor in our finance organization over the past
five years, and we believe he is an excellent choice to succeed
Bill as our CFO.”
Biographies
Mr. Knight joined Bruker Corporation as CFO and Treasurer in
October 2004. At Bruker, Mr. Knight is also the President of the
Bruker Detection business in the United States. Before joining the
Company, Mr. Knight served as an operations-focused CFO in
several public companies, and was a founder of ATI Technologies, an
analytical instruments company, where he had both financial and
operational responsibilities. Mr. Knight served as CFO of Anika
Therapeutics, Inc., from 2002 to 2004. He served as CFO of
Zycos, Inc., a developer of DNA-based therapeutic products,
from 2000 to 2002, and as CFO of NMT Medical, Inc., a provider
of cardiovascular and neurological medical devices, from 1998 to
2000. Mr. Knight is a Certified Public Accountant and holds a
B.B.A. in Accounting from the University of Wisconsin.
Mr. Monahan joined Bruker Corporation as the Corporate
Controller in April 2004 and was appointed Chief Accounting Officer
and Vice President of Finance in March 2009. In addition to his
corporate responsibilities, Mr. Monahan has served in both
financial and operational roles in the Bruker Daltonics division,
where he has been an Executive Vice President of Bruker Daltonics
since November 2006 and General Manager of the Americas since July
2008. From January 2005 to November 2006, Mr. Monahan was Vice
President of Finance for Bruker Daltonics, and from July 2004 to
January 2005 he was Assistant Vice President of Finance for Bruker
Daltonics. Before joining the Company, from 2002 through 2004,
Mr. Monahan served as the Manager of Accounting and Financial
Reporting at Fisher Scientific International, Inc., and as an
audit manager for PricewaterhouseCoopers LLP from 1999 through
2002. Mr. Monahan is a Certified Public Accountant and holds a
B.S. in Accounting from the University of Massachusetts.
ABOUT BRUKER CORPORATION
Bruker Corporation is a leading provider of high-performance
scientific instruments and solutions for molecular and materials
research, as well as for industrial and applied analysis. For more
information about Bruker Corporation, please visit
www.bruker.com.
CAUTIONARY STATEMENT
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to risks and
uncertainties, that could cause actual future results to differ
materially from those projected including, but are not limited to,
risks and uncertainties relating to adverse changes in conditions
in the global economy and volatility in the capital markets, the
integration of businesses we have acquired or may acquire in the
future, changing technologies, product development and market
acceptance of our products, the cost and pricing of our products,
manufacturing, competition, dependence on collaborative partners
and key suppliers, capital spending and government funding
policies, changes in governmental regulations, realization of
anticipated benefits from economic stimulus programs, intellectual
property rights, litigation, and exposure to foreign currency
fluctuations and other risk factors discussed from time to time in
our filings with the Securities and Exchange Commission. These and
other factors are identified and described in more detail in our
filings with the SEC, including, without limitation, our recent
Proxy Statements on Schedule 14A, our annual report on Form 10-K
for the year ended December 31, 2008, our most recent quarterly
reports on Form 10-Q and our current reports on Form 8-K. We
expressly disclaim any intent or obligation to update these
forward-looking statements other than as required by law.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024